CAB-ROR2-ADC for Melanoma

Phase-Based Progress Estimates
Melanoma+6 More
CAB-ROR2-ADC - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Melanoma
  • Breast Cancer (Triple Negative Breast Cancer (TNBC))
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Head and Neck Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Melanoma

Study Objectives

7 Primary · 13 Secondary · Reporting Duration: Up to 24 months

Week 3
Dose Limiting Toxicities (DLTs)
Week 3
Maximum Tolerated Dose (MTD)
Up to 24 months
Anti-tumor activity
Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3021)
Immunogenicity of BA3021
Pharmacokinetics; AUC
Pharmacokinetics; Cmax
Phase 1 and 2: Best overall response (OR)
Phase 1 and 2: Disease control rate (DCR)
Phase 1 and 2: Duration of response (DOR)
Phase 1 and 2: Overall survival (OS)
Phase 1 and 2: Progression-free survival (PFS)
Phase 1 and 2: Safety Profile
Phase 1 and 2: Time to response (TTR)
Phase 1 and 2: Tumor size
Phase 1: Confirmed Objective Response Rate (ORR)
Phase 1: Immunogenicity
Phase 1: Pharmacokinetics
Phase 1: Safety Profile
Phase 2: Confirmed Objective Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Other trials for Melanoma

Trial Design

2 Treatment Groups

Monotherapy - CAB-ROR2-ADC (BA3021) alone
1 of 2
Combination Therapy
1 of 2
Experimental Treatment

420 Total Participants · 2 Treatment Groups

Primary Treatment: CAB-ROR2-ADC · No Placebo Group · Phase 1 & 2

Monotherapy - CAB-ROR2-ADC (BA3021) alone
Experimental Group · 1 Intervention: CAB-ROR2-ADC · Intervention Types: Biological
Combination TherapyExperimental Group · 2 Interventions: CAB-ROR2-ADC, PD-1 inhibitor · Intervention Types: Biological, Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
PD-1 inhibitor
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

BioAtla, Inc.Lead Sponsor
5 Previous Clinical Trials
496 Total Patients Enrolled
2 Trials studying Melanoma
156 Patients Enrolled for Melanoma
Yong BenStudy DirectorBioAtla, Inc.
Philippe MartinStudy DirectorBioAtla, Inc.

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS) are eligible for this study.
You have adequate renal function.
You have an ECOG performance status of 0 or 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.